<DOC>
	<DOC>NCT01849185</DOC>
	<brief_summary>The primary objective is to examine whether probiotics given to hypercholesterolemic patients treated with statins, would further decrease LDL-Cholesterol levels. The secondary objective is to examine whether adding of probiotics to statins would decrease fasting glucose levels and glycolysated hemoglobin</brief_summary>
	<brief_title>Probiotic BIO-25 as a Supplement to Statins for the Treatment of Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>1) Patients on maximal tolerated dose of conventional statins treated for at least eight weeks on simvastatin 40, pravastatin 40, atorvastatin 4080 or rosuvastatin 2040 mg, who failed to achieve target values of LDLcholesterol according to the European Socety Cardiology guidelines 2012. 1. Patients on chronic antibiotic treatment 2. Patients with immune disorders 3. Patients who are not receiving maximal dose of statin therapy or receive combination of statins for dyslipidemia. 4. Patients who experienced myocardial infarction within less than two months. 5. Patients who consume probiotics.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Hypercholesterolemia</keyword>
</DOC>